The COVID-19 pandemic and the use of MS disease-modifying therapies
Gavin Giovannoni, Chris Hawkes, Jeannette Lechner‐Scott, Michael Levy, Emmanuelle Waubant, Julian Gold
Topics & Concepts
OcrelizumabMedicinePandemicMultiple sclerosisCoronavirus disease 2019 (COVID-19)NeurologyInterferon beta-1aIntensive care medicineCoronavirusDiseasePediatricsInterferon betaInternal medicineInfectious disease (medical specialty)PsychiatryRituximabLymphomaMultiple Sclerosis Research StudiesLong-Term Effects of COVID-19Polyomavirus and related diseases